Back to Peptides

ARA-290

Healing & Regeneration

ARA-290 is a non-erythropoietic peptide derived from erythropoietin that targets the innate repair receptor (IRR) to reduce inflammation and promote healing, particularly in neuropathic pain, cardiovascular inflammation, and microvascular dysfunction. It avoids stimulating red blood cell production, making it safer for chronic therapeutic use.

Reconstitute
2 mL BAC + 16mg vial
80 mcg/unit
Daily Range
1–8 mg Subcutaneous (SQ)
daily
Standard Dose
4 mg
Cycle
4–8 weeks
then reassess
ErythropoietinInflammationTissue ProtectionNeuropathy

Dosing & Reconstitution Guide

In animal studies, ARA-290 is typically administered via subcutaneous injection at doses ranging from 30–100 μg/kg. Human clinical research has tested 2–4 mg/day for short durations under controlled conditions. These are investigational only.

Standard / Gradual Approach

16mg Vialstandard
PhaseDoseVolume
Week 12 mg (2,000 mcg)25 units (0.25 mL)
Weeks 2–8 (or up to 16)4 mg (4,000 mcg)50 units (0.50 mL)

Protocol Summary

Subcutaneous (SQ): daily · Dose range 1–8 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

Recommended frequency: 3–5x per week with a suggested cycle length of 4–8 weeks, followed by reevaluation.

🧪 Quick Start

Vial Size
16 mg
BAC Water
2 mL
Concentration
8 mcg/unit
Starting Dose
2 mg (2,000 mcg) (25 units (0.25 mL))
Maintenance Dose
4 mg (4,000 mcg) (50 units (0.50 mL))

Potential Benefits & Use Cases

ARA-290 is an investigational research peptide. It is not approved for human or veterinary use. All information provided is for research and educational purposes only.
Improves HbA1c, lipid profiles, and neuropathic pain scores in diabetic neuropathy trials at 4 mg daily (human trial)
Increases corneal nerve fiber density in sarcoidosis-associated small-fiber neuropathy — objective nerve regrowth (Phase 2)
Granted FDA orphan drug designation for sarcoidosis-associated small-fiber neuropathy (regulatory)
Demonstrates anti-inflammatory and anti-apoptotic effects across multiple organ systems (preclinical)
Does not stimulate red blood cell production unlike full EPO, avoiding related side effects (preclinical)
Clinical data Strong preclinical Limited data

Mechanism of Action

→Reduces inflammation
→Promotes tissue repair
→Binds to the innate repair receptor (IRR) composed of EPO-R and CD131
→Suppresses microglial activation in the spinal cord
→Reduces pro-inflammatory cytokine activity
→Improves microvascular function and nerve regeneration

Lifestyle & Optimization

timing

Consistent injection schedule.

diet

Optimize glycemic control. Avoid smoking and limit alcohol.

exercise

Appropriate physical activity for nerve health.

sleep

Adequate sleep and stress management.

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
Molecular Medicine (PMC) — ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber lossReference
PLOS ONE — Cibinetide (ARA 290) improves corneal nerve fiber abundance in patients with sarcoidosisReference
Science Translational Medicine — Tissue-protective erythropoietin receptor signaling (non-hematopoietic pathway)Reference
PMC (Molecular Medicine) — Safety, tolerability and efficacy of ARA 290 in sarcoidosisReference
ClinicalTrials.gov — NCT02039752: Cibinetide (ARA 290) Phase 2 trial in Type 2 diabetes patients with neuropathyReference
Stem Cells Translational Medicine — ARA 290 promotes wound healing in diabetic miceReference
Frontiers in Immunology — Non-hematopoietic EPO receptor signaling in tissue protectionReference

Side Effects & Safety

Common Side Effects

• Transient headache, mild dizziness (human trial)
• Fatigue after dosing (human trial)
• Mild GI discomfort (human trial)

🧮 Dose Calculator

Concentration
80.0
mcg/unit
Draw Volume
6
units (0.060 mL)
For a 500 mcg dose, draw 6 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
High bioavailability when administered subcutaneously.
Oral Administration
Not orally bioavailable.
Intranasal
Intramuscular route is used in some studies for localized effects.
Half-Life
Approximately 2 hours
Degradation
Mainly metabolized by endothelial cells and degraded by proteases.
Tissue Specificity
Interacts primarily with nervous and immune tissues to exert protective and reparative effects.
⚗️

Peptide Details

Molecular Weight
14179.3
Formula
C141H210N38O41
Sequence
Ac-VSPKVGSEAEABQPLPLRSLS
⚖️

Legal Status & Regulatory

RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved

Storage Instructions

Lyophilized (Powder)
refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); reconstituted: refrigerate and use within 28 days
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days and do not freeze the liquid solution